At the 2024 European Society for Medical Oncology (ESMO) Congress, Kangfang Biotech (HKG: 9926) unveiled for the first time the results of its independently developed PD-1/VEGF bispecific antibody, Yivoxi, used in combination with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic triple-negative breast cancer (TNBC). Preliminary data with a median follow-up of only 10 months demonstrated the superior efficacy and favorable safety profile of the Yivoxi combination regimen in first-line TNBC treatment.
The study, co-led by Professor Wang Xiaojia from Zhejiang Cancer Hospital, presented an oral report at the congress. As of May 31, 2024, the study enrolled 30 patients with locally advanced unresectable or metastatic TNBC. Notably, 80% of the enrolled patients were PD-L1 expression negative (PD-L1 CPS <10), and 60% had previously received taxane-based adjuvant/neoadjuvant therapy, a proportion higher than that in similar target drug-related studies.
Although the follow-up time was short and the data are not yet mature, the study still showed that the Yivoxi regimen provided significant progression-free survival (PFS) benefits for TNBC patients, with a safety profile consistent with previous Yivoxi-related research. – Flcube.com
